AHR and Autoimmunity: Evidence from studies to control autoimmunity and graft-vs.-host disease, even virus induced inflammatory lesions indicate that the regulation of the immune response to avoid immunopathology could be achieved by the administration of the stable agonist of AhR, TCDD (7, 39–41).